{"id":87928,"date":"2026-10-19T18:40:00","date_gmt":"2026-10-19T18:40:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=87928"},"modified":"2026-10-20T01:54:31","modified_gmt":"2026-10-20T01:54:31","slug":"migraine-market-is-expected-to-expand-at-6-growth-rate-by-2036-owing-to-the-development-of-novel-mechanisms-beyond-cgrp-including-pacap-targeted-therapies-trpa1-antagonists-and-next-generation-neu","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/migraine-market-is-expected-to-expand-at-6-growth-rate-by-2036-owing-to-the-development-of-novel-mechanisms-beyond-cgrp-including-pacap-targeted-therapies-trpa1-antagonists-and-next-generation-neu\/","title":{"rendered":"Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight"},"content":{"rendered":"

The migraine market is expected to grow steadily over the forecast period (2026\u20132036) driven by the rising global prevalence of migraine, improving diagnosis rates, and increasing awareness of chronic and high-frequency migraine. In addition, the introduction of novel, differentiated therapies such as Elismetrep (Kallyope), Dysport (abobotulinumtoxinA; Ipsen), Xeomin (incobotulinumtoxinA; Merz Therapeutics GmbH), Bocunebart (AG09222; Lundbeck), EVO756 (Evommune), and others that move beyond traditional acute treatments is expected to further expand the market.<\/em><\/p>\n

New York, USA, Oct. 19, 2026 (GLOBE NEWSWIRE) — Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight<\/b><\/p>\n

The migraine market is expected to grow steadily over the forecast period (2026\u20132036) driven by the rising global prevalence of migraine, improving diagnosis rates, and increasing awareness of chronic and high-frequency migraine. In addition, the introduction of novel, differentiated therapies such as Elismetrep (Kallyope), Dysport (abobotulinumtoxinA; Ipsen), Xeomin (incobotulinumtoxinA; Merz Therapeutics GmbH), Bocunebart (AG09222; Lundbeck), EVO756 (Evommune), and others that move beyond traditional acute treatments is expected to further expand the market.<\/i><\/b><\/p>\n

Recently published Migraine Market Insights report includes a comprehensive understanding of current treatment practices, migraine emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].<\/p>\n

Migraine Market Summary<\/b><\/p>\n